Malakhov V I, Golitsyn S P, Sokolov S F, Bakalov S A, Levin E R, Mikhaĭlova G A, Krutanov I B
Ter Arkh. 1991;63(9):32-8.
As many as 30 patients with different pathologies of the cardiovascular system and paroxysms of ventricular tachycardias were examined. According to the ultrasonography data, an ejection fraction was not lower than 35% in all the patients. It has been shown by electrophysiological studies that intravenous injection of ethacizine in a dose of 0.6 +/- 0.1 mg/kg prevented induction of ventricular tachycardia in 66.7% of patients. In 16.7% of patients, the drug exerted an arrhythmogenic effect that showed up by a decrease of the cycle of tachycardia. Oral administration of ethacizine in the daily dose 100 or 150 mg prevented tachycardia induction by endocardial stimulation in 20.8% of patients. The arrhythmogenic effect of the drug was recorded in 12.5% of patients. The action of ethacizine when administered by both routes was accompanied by a significant elongation of the P--Q interval, QRS complex and of the cycle of ventricular tachycardia. Continuous administration of ethacizine in the daily dose 150 mg to patients with a positive antiarrhythmic drug action (according to the electrophysiological data) prevented paroxysms of ventricular tachycardia, with the observation period being 2 to 6.5 years.
对多达30例患有不同心血管系统疾病且伴有室性心动过速发作的患者进行了检查。根据超声心动图数据，所有患者的射血分数均不低于35%。电生理研究表明，静脉注射剂量为0.6±0.1mg/kg的乙吗噻嗪可使66.7%的患者预防室性心动过速的诱发。在16.7%的患者中，该药物产生了致心律失常作用，表现为心动过速周期缩短。每日口服100或150mg乙吗噻嗪可使20.8%的患者通过心内膜刺激预防心动过速诱发。在12.5%的患者中记录到该药物的致心律失常作用。乙吗噻嗪经两种途径给药时，均伴有P-Q间期、QRS波群和室性心动过速周期的显著延长。对具有抗心律失常药物阳性作用（根据电生理数据）的患者连续每日给予150mg乙吗噻嗪，可预防室性心动过速发作，观察期为2至6.5年。
